Dry Age-Related Macular Degeneration Market Size, Share, Growth, Industry Analysis, Trends and Dynamics, By Types (Oral, Injectables), By Applications (Above 40 Years, Above 60 Years, Above 75 Years), Regional Insights and Forecast to 2035

Dry Age-Related Macular Degeneration Market Size

The Global Dry Age-Related Macular Degeneration Market size was USD 1567.7 Million in 2025 and is projected to reach USD 1669.58 Million in 2026, USD 1778.2 Million in 2027, and USD 2942.82 Million by 2035, exhibiting a CAGR of 6.5% during the forecast period 2026–2035.

The Dry Age-Related Macular Degeneration Market is moving from largely supportive disease management toward therapies designed to slow retinal degeneration and preserve functional vision. Advanced dry AMD and geographic atrophy are attracting greater clinical attention as diagnosis improves and treatment options broaden. Approximately 63% of addressable demand is associated with older patients requiring continuous retinal monitoring, while nearly 34% of treatment expansion is linked to improved specialist referrals and earlier identification of disease progression.

In the US Dry Age-Related Macular Degeneration Market, adoption is supported by a large aging population, established retina-specialist networks, and increasing utilization of advanced imaging. The country represents an estimated 31% of global treatment activity, while approximately 44% of eligible advanced-stage patients are increasingly considered for active therapeutic intervention rather than observation alone.

Key Findings

• Market Size: Starting at $1669.58M in 2026, projected to reach $1778.2M in 2027 and $2942.82M by 2035 at a CAGR of 6.5%.
• Growth Drivers: Aging demographics contribute nearly 32% of demand momentum, while improving geographic atrophy diagnosis supports approximately 24% of treatment expansion.
• Trends: Complement-targeted therapies influence about 29% of treatment decisions, while longer-duration and non-intravitreal approaches represent nearly 21% of pipeline interest.
• Key Players: Santen Pharmaceuticals, Allergan, Iveric Bio, Belite Bio, Eyestem Research & more.
• Regional Insights: North America holds 37%, Europe 28%, Asia-Pacific 26%, and Middle East & Africa 9% of the overall market.
• Challenges: Treatment burden affects nearly 31% of eligible patients, while specialist-access limitations influence approximately 22% of potential therapy uptake.
• Industry Impact: Advanced retinal imaging supports around 28% better patient identification, while structured monitoring pathways improve treatment continuity by approximately 19%.
• Recent Developments: Late-stage clinical programs represent roughly 36% of active innovation, while alternative administration approaches account for approximately 23% of pipeline differentiation.

The Dry Age-Related Macular Degeneration Market is increasingly defined by disease-stage segmentation rather than a single treatment pathway. Nearly 39% of innovation activity is focused on geographic atrophy, while approximately 27% targets earlier intervention, retinal preservation, or slowing progression before irreversible central vision loss becomes dominant.

Competitive positioning increasingly depends on clinical durability, administration convenience, safety, and measurable preservation of retinal tissue. Approximately 35% of physician preference is influenced by treatment burden, while nearly 26% is associated with evidence demonstrating sustained slowing of lesion progression and preservation of functional vision.

Dry Age-Related Macular Degeneration Market Trends

The Dry Age-Related Macular Degeneration Market is undergoing a meaningful transition as therapeutic development increasingly addresses the biological mechanisms involved in progressive retinal degeneration. Complement inhibition remains an important treatment direction, but research programs are expanding toward mitochondrial protection, visual-cycle modulation, cell replacement, and other disease-modifying mechanisms. Approximately 38% of advanced development activity is concentrated on therapies intended to slow geographic atrophy lesion expansion, while nearly 24% is associated with approaches designed to reduce treatment frequency or provide longer-lasting effects. This shift reflects growing recognition that patient acceptance depends on more than clinical efficacy alone. Injection frequency, monitoring requirements, safety considerations, and preservation of everyday visual function are becoming important determinants of therapeutic differentiation.

Another major trend is the increasing role of retinal imaging and biomarker-supported patient selection. Optical coherence tomography, fundus autofluorescence, and complementary imaging techniques enable clinicians to detect progression patterns before severe central vision deterioration develops. Around 42% of specialist-driven treatment decisions increasingly incorporate detailed lesion characteristics, while approximately 30% of clinical-development strategies emphasize structural retinal endpoints alongside conventional visual-acuity measurements. Oral therapies, cell-based interventions, and longer-duration approaches are also receiving greater attention because they could reduce dependence on frequent intravitreal administration. These developments are gradually creating a more segmented Dry Age-Related Macular Degeneration Market in which therapeutic choice depends on lesion location, progression rate, patient age, treatment tolerance, and individual risk profile.

Dry Age-Related Macular Degeneration Market Dynamics

OPPORTUNITY

Expansion of disease-modifying and lower-burden treatment approaches

A substantial opportunity exists in therapies capable of slowing retinal degeneration while reducing treatment burden. Nearly 41% of potential patients remain outside active advanced-therapy pathways because of eligibility, access, administration concerns, or limited disease-stage options. Approximately 27% of emerging clinical interest is therefore shifting toward oral therapies, sustained-action approaches, mitochondrial protection, and regenerative strategies. Successful products that combine durable retinal protection with convenient administration could expand treatment beyond the most advanced geographic atrophy population. Earlier diagnosis further increases this opportunity by allowing physicians to identify progressive disease before severe central retinal damage substantially limits functional vision.

DRIVERS

Growing diagnosis of geographic atrophy among aging populations

Population aging and improved retinal screening are expanding the identifiable treatment population. Approximately 46% of clinically significant dry AMD burden is concentrated among older adults requiring repeated ophthalmic evaluation, while improved imaging could increase recognition of progressive atrophic lesions by about 25%. Greater awareness among ophthalmologists, optometrists, patients, and caregivers is encouraging earlier referral to retina specialists. As approved and investigational therapies establish dry AMD as a treatable rather than exclusively monitored condition, screening intensity and longitudinal disease management are expected to increase further, supporting sustained demand across specialist clinics and ophthalmology centers.

RESTRAINTS

"High treatment burden limits broader patient participation"

Repeated treatment and monitoring requirements remain a major restraint, particularly for elderly patients who depend on caregivers or travel considerable distances to retina specialists. Approximately 29% of eligible patients may experience adherence pressure from repeated ophthalmic visits, while around 18% face practical access limitations associated with specialist availability. Current therapies primarily slow disease progression rather than restore retinal tissue, which can also moderate patient expectations. Treatment decisions therefore require careful balancing of potential structural benefit, administration burden, safety monitoring, disease severity, and the patient's ability to maintain long-term follow-up.

CHALLENGES

"Demonstrating meaningful functional vision benefits"

A central challenge is translating measurable reductions in lesion progression into outcomes patients clearly recognize in everyday vision. Structural retinal endpoints can show biological activity before substantial differences emerge in conventional visual-acuity measurements. Nearly 33% of development complexity is linked to selecting sensitive clinical endpoints, while approximately 21% relates to identifying patients whose progression profile can demonstrate therapeutic benefit within practical trial periods. Developers must therefore integrate imaging, low-luminance vision, retinal sensitivity, lesion location, and functional measures to establish stronger evidence that slowing anatomical deterioration produces meaningful long-term benefits for patients.

Segmentation Analysis

The Dry Age-Related Macular Degeneration Market can be segmented by treatment type and patient age, with each segment reflecting different therapeutic needs and disease severity. Injectables currently account for approximately 68% of active advanced-treatment demand because intravitreal approaches have established clinical relevance in geographic atrophy. Oral therapies represent an emerging opportunity, particularly where systemic or visual-cycle mechanisms can support convenient long-term treatment. Patient segmentation is increasingly concentrated among older populations because disease prevalence and progression risk rise substantially with age.

By Type

Oral

Oral therapies represent an important emerging segment because they offer the potential to reduce procedural burden and improve long-term adherence. Approximately 24% of development interest is associated with non-intravitreal treatment approaches, while nearly 31% of surveyed treatment considerations can be influenced by administration convenience. Oral candidates targeting visual-cycle biology or other retinal degeneration mechanisms could broaden treatment participation among patients reluctant or unable to undergo frequent ocular injections. Their commercial potential will depend heavily on durable efficacy, systemic safety, patient selection, and evidence of meaningful retinal preservation.

Injectables

Injectables remain the most established therapeutic category for advanced dry AMD and geographic atrophy. Approximately 68% of active treatment utilization is concentrated in intravitreal approaches, reflecting established retinal drug-delivery pathways and direct administration to ocular tissues. Around 37% of specialist preference is influenced by demonstrated lesion-growth reduction and accumulated clinical experience. Future injectable competition will increasingly focus on longer dosing intervals, safety, reduced injection burden, and the ability to demonstrate progressive treatment benefit over extended periods rather than only short-term anatomical improvement.

By Application

Above 40 Years

The above 40 years segment primarily represents early detection, risk assessment, and long-term monitoring rather than the largest share of advanced treatment. Approximately 14% of addressable clinical activity is associated with this broader age category, while nearly 22% of preventative ophthalmic assessment can originate from patients with family history, smoking exposure, metabolic risk, or early retinal changes. Earlier recognition in this population creates an opportunity for monitoring and future intervention before substantial geographic atrophy develops.

Above 60 Years

Patients above 60 years represent a major demand group because dry AMD prevalence rises considerably with advancing age. Approximately 38% of market-related patient management is concentrated within this segment, while around 34% of specialist monitoring intensity is associated with identifying progression from intermediate disease toward advanced retinal atrophy. Improved imaging and expanding therapeutic options encourage closer follow-up, making this population important for both current intervention and future disease-modifying treatment strategies.

Above 75 Years

The above 75 years group represents the most clinically significant application segment because advanced retinal degeneration becomes increasingly common in older patients. Approximately 48% of advanced-treatment demand is associated with this age category, while close to 41% of treatment-planning complexity involves mobility, comorbidities, caregiver dependence, or repeated specialist visits. Therapies offering longer duration, simpler administration, or reduced monitoring could generate particularly strong value within this population by improving treatment continuity and accessibility.

Dry Age-Related Macular Degeneration Market Regional Outlook

Regional performance reflects differences in aging demographics, ophthalmology infrastructure, reimbursement, diagnostic penetration, and access to retinal specialists. North America accounts for 37% of the market, Europe 28%, Asia-Pacific 26%, and Middle East & Africa 9%, collectively representing 100%. Treatment adoption remains strongest where advanced imaging, retina-specialist capacity, and structured reimbursement pathways are established, while developing regions provide longer-term opportunity through expanding diagnostic infrastructure and specialist training.

North America

North America holds approximately 37% of the Dry Age-Related Macular Degeneration Market, supported by strong retinal-specialist density, advanced diagnostic infrastructure, and earlier uptake of disease-modifying treatments. The United States accounts for most regional demand, while approximately 45% of advanced-patient management increasingly incorporates high-resolution retinal imaging and structured follow-up. Competitive intensity is also high because commercial therapies and late-stage investigational programs frequently establish their initial clinical and adoption pathways within the region.

Europe

Europe represents approximately 28% of the global market, supported by aging populations and established ophthalmology systems across major Western European countries. Nearly 36% of regional growth potential is associated with improving geographic atrophy identification and expanding access to advanced retinal treatment. Adoption remains uneven because reimbursement assessment, country-level treatment protocols, and specialist capacity vary substantially. Wider availability of disease-modifying options could strengthen referrals and increase systematic monitoring of patients progressing from intermediate dry AMD toward advanced atrophy.

Asia-Pacific

Asia-Pacific holds approximately 26% of the market and presents strong long-term potential because of its large aging population and expanding ophthalmic infrastructure. Nearly 32% of regional opportunity is linked to improving access to retinal imaging and specialist services across major urban healthcare systems. Clinical-development activity is also broadening, including oral and regenerative approaches. Rising disease awareness, expanding treatment capacity, and greater participation in multinational ophthalmology trials are gradually narrowing the historical diagnostic and therapeutic gap with developed Western markets.

Middle East & Africa

Middle East & Africa accounts for approximately 9% of the global market. Specialist retinal care remains concentrated in major urban healthcare centers, producing considerable differences in diagnosis and treatment access. Approximately 24% of regional market development is associated with private ophthalmology networks and specialized hospitals, while around 18% relates to expanding imaging capacity and physician training. Long-term growth depends on broader screening, stronger referral pathways, improved affordability, and increased availability of advanced therapies beyond high-income metropolitan healthcare systems.

List of Key Dry Age-Related Macular Degeneration Market Companies Profiled

Investment Analysis and Opportunities

Investment in the Dry Age-Related Macular Degeneration Market is increasingly directed toward differentiated mechanisms capable of reducing treatment burden or preserving retinal function for longer periods. Approximately 36% of development-oriented investment interest is concentrated on geographic atrophy, while nearly 25% targets oral, regenerative, mitochondrial, or longer-duration therapeutic concepts. Attractive opportunities exist in biomarker development, retinal imaging, patient-selection technologies, drug-delivery systems, and therapies addressing earlier disease stages. Companies demonstrating meaningful functional outcomes alongside anatomical lesion control could attract greater strategic interest because current market needs extend beyond simply slowing structural deterioration. Partnerships between biotechnology developers, ophthalmology specialists, and larger pharmaceutical organizations are also likely to remain important for late-stage development and commercialization.

New Products Development

New product development is widening beyond conventional complement inhibition toward mechanisms addressing multiple pathways involved in retinal degeneration. Approximately 34% of emerging innovation is focused on alternative biological mechanisms, while about 23% emphasizes treatment formats intended to reduce repeated intravitreal administration. Oral visual-cycle modulators, mitochondrial-targeted therapies, retinal pigment epithelium cell replacement, and longer-duration ocular therapies illustrate this diversification. Developers are increasingly designing products around both structural and functional outcomes, recognizing that patients and specialists require evidence of preserved useful vision. Future differentiation will depend on safety, dosing convenience, treatment durability, lesion-growth control, and whether products can address patients earlier in the disease pathway before irreversible central retinal damage occurs.

Recent Developments

• February 2024– Belite Bio expanded the PHOENIX geographic atrophy program: Belite Bio advanced the geographic atrophy development pathway for oral Tinlarebant through additional European clinical authorization for its Phase 3 program. The development strengthened the geographic reach of an oral approach to advanced dry AMD. The program is designed to address retinal degeneration through visual-cycle modulation, adding diversity to a market where approximately 68% of current active treatment use remains associated with injectable approaches.

• September 2024– Eyestem Research initiated patient treatment with Eyecyte-RPE: Eyestem Research completed treatment of its first patient cohort using its retinal pigment epithelium cell suspension for geographic atrophy secondary to dry AMD. The initial three patients represented approximately 8.3% of the planned 36-patient study population. The program is significant because it evaluates regenerative replacement of damaged retinal cells rather than solely slowing inflammatory or complement-mediated degeneration.

• February 2025– Iveric Bio-originated IZERVAY gained broader dosing flexibility: The geographic atrophy therapy originally developed by Iveric Bio received expanded U.S. prescribing flexibility without a fixed limitation on treatment duration. Earlier clinical evidence showed approximately 18% reduction in geographic atrophy growth in one pivotal study and up to 35% in another analysis, reinforcing sustained complement inhibition as an established therapeutic strategy in advanced dry AMD.

• March 2025– Stealth Biotherapeutics reached major ReNEW enrollment milestone: Stealth Biotherapeutics reported that its Phase 3 ReNEW study of elamipretide had reached 50% of its planned enrollment. The program evaluates mitochondrial-targeted therapy in dry AMD and represents an important alternative to complement-directed mechanisms. Its development highlights increasing emphasis on preserving retinal cellular function through pathways potentially relevant before or alongside advanced geographic atrophy progression.

• July 2025– Belite Bio completed PHOENIX enrollment: Belite Bio completed 100% of planned enrollment in its pivotal global PHOENIX study evaluating oral Tinlarebant in geographic atrophy associated with dry AMD. The milestone strengthened prospects for a non-intravitreal treatment option and is strategically important because oral administration could reduce procedural burden for older patients who currently depend heavily on repeated specialist visits and ocular injections.

Report Coverage

The Dry Age-Related Macular Degeneration Market report covers market structure, treatment trends, growth dynamics, investment priorities, competitive positioning, segmentation, regional performance, clinical innovation, and emerging product development. The analysis evaluates Oral and Injectables as the specified treatment types and examines Above 40 Years, Above 60 Years, and Above 75 Years as the defined application groups. Injectables account for approximately 68% of current active advanced-treatment utilization, while oral and alternative approaches represent a growing pipeline opportunity. Regional analysis allocates 37% share to North America, 28% to Europe, 26% to Asia-Pacific, and 9% to Middle East & Africa, producing a complete 100% geographic distribution. Competitive coverage includes Santen Pharmaceuticals, Allergan, Bausch Health, Alimera Science, Phio Pharmaceuticals, Ocumension Therapeutics, Belite Bio, Kubota Vision, Iveric Bio, Eyestem Research, Y2 Solution, and Stealth Biotherapeutics. The report also evaluates diagnostic expansion, treatment burden, retinal imaging, aging demographics, disease-modifying therapies, regenerative approaches, clinical-development activity, and opportunities for therapies capable of preserving retinal structure while improving long-term treatment convenience.